Royalty Pharma

Royalty Pharma is one of the...

• Forbes Global 2000 (#1894);
• Russell 3000.

Royalty Pharma is a company listed under the stock ticker RPRX (US).

View the org chart displaying its 37 main executives

Most searched biographies at Royalty Pharma

• Pablo Legorreta, Chairman of the Board, Founder and Chief Executiv...
• Ted Love, Director
• David Hodgson, Director

Popular executive movements at Royalty Pharma

• Eric Schneider has joined the company as Senior Vice President and Chief Technology Officer  (posted on September 22 2023).

Create your alert
to follow the executive moves at Royalty Pharma.

Royalty Pharma has 1,817 competitors including Siemens Healthineers (Germany), IQVIA (United States (USA)) and Saint Francis Health System (United States (USA)).

Popular M&A news in Healthcare

• Two Chairs has just announced a $72 Million fundraising (posted on April 18 2024).
• Grow Therapy has just announced a $88 Million fundraising (posted on April 12 2024).
• SSI Strategy and NDA Group have announced they will merge  (posted on April 8 2024)..

Popular contacts in Healthcare

• Ari Bousbib - Chairman and Chief Executive Officer at IQVIA
• Ralph De La Torre - Chairman and Chief Executive Officer at Steward Health Care
• Sima Sistani - Chief Executive Officer and Director at WW International

Learn more about the Healthcare industry >

Press releases by Royalty Pharma

• Royalty Pharma Declares Third Quarter 2022 Dividend | Royalty Pharma
• Press Releases | Royalty Pharma
• Royalty Pharma to Announce Second Quarter 2022 Financial Results on August 4, 2022 | Royalty Pharma
• Royalty Pharma Agrees to Acquire Royalty Interest in Trelegy Ellipta From Theravance and Innoviva for $1.31 Billion and Potential Milestones of $300 Million | Royalty Pharma
• Royalty Pharma Acquires Royalty Interest in Gavreto From Blueprint Medicines for up to $340 Million | Royalty Pharma
• Royalty Pharma to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference | Royalty Pharma
• Royalty Pharma to Present at the UBS Global Healthcare Conference 2022 | Royalty Pharma
• Royalty Pharma Investor Day Highlights Stronger Growth Outlook and the Power of Its Unique Business Model to Drive Value for All Stakeholders | Royalty Pharma
• Royalty Pharma Announces Charitable Alliance with Mount Sinai | Royalty Pharma
• Royalty Pharma Reports First Quarter 2022 Results | Royalty Pharma
• View more press releases Close

Social media about Royalty Pharma

• Royalty Pharma on Wikipedia, Google News & Yahoo Finance
• Royalty Pharma on LinkedIn, Twitter & YouTube

Contact by email its executives including Pablo Legorreta

Call Royalty Pharma at +1 212...

View the org chart

Register to receive your alert

Report an error